Idelalisib

證據等級: L5

預測適應症: 10 個

IDELALISIB: From B-cell Lymphoid Malignancies to Mantle Cell Lymphoma

One-Sentence Summary

Idelalisib is a selective PI3Kδ inhibitor originally developed for B-cell lymphoid malignancies (chronic lymphocytic leukemia, follicular lymphoma, small lymphocytic lymphoma). The TxGNN model predicts it may also be effective for Mantle Cell Lymphoma (MCL), with 9 clinical trials and 20 publications currently supporting this direction — though confirmatory Phase 2/3 evidence specific to MCL is still lacking.

Quick Overview

Item	Content
Original Indication	Not stated in evidence pack (data gap — `drug.original_indications` is empty). Based on the drug's known identity (idelalisib/Zydelig®) referenced throughout the evidence pack's own mechanistic rationale, the drug's established indications are relapsed CLL, follicular lymphoma, and small lymphocytic lymphoma.
Predicted New Indication	Mantle Cell Lymphoma
TxGNN Prediction Score	99.84% (rank 2395)
Evidence Level	L3
Germany Market Status	未上市 (Not marketed) — flagged internally as a likely data gap rather than a true absence of licensure (see rationale below)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured drug.original_moa field (data gap, item DG002). Based on information embedded elsewhere in this evidence pack, idelalisib is a selective, orally bioavailable inhibitor of the δ-isoform of phosphatidylinositol 3-kinase (PI3Kδ). PI3Kδ signaling is a core component of the B-cell receptor (BCR) pathway, which drives survival and proliferation in multiple B-cell malignancies.

Mantle cell lymphoma is, like idelalisib's established indications (CLL, FL, SLL), a BCR-signaling-dependent B-cell lymphoma. This shared molecular dependency is the biological basis for the TxGNN prediction: a drug validated against one BCR-driven malignancy is mechanistically plausible against another. In vitro studies included in this evidence pack directly support this — idelalisib inhibits growth and induces apoptosis in MCL cell lines (PMID 27342398, PMID 33850273, PMID 40466505), and an early-phase clinical study reported measurable single-agent activity in relapsed/refractory MCL patients (PMID 24795031, PMID 24615778).

At the same time, the evidence pack itself notes that idelalisib shows intrinsic resistance in a subset of MCL cases (PMID 33850273), and several trials combining idelalisib with other agents in MCL were terminated early (e.g., NCT01796470, NCT02457598) — indicating that while the mechanistic rationale is sound, clinical translation in MCL specifically has not yet been confirmed at a definitive level.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01088048	Phase 1	Completed	241	Safety of idelalisib combined with anti-CD20 mAb, chemotherapy, mTOR/protease/antiangiogenic/immunomodulatory agents in relapsed/refractory iNHL, MCL, or CLL
NCT01838434	Phase 1	Completed	106	Idelalisib + lenalidomide in relapsed/refractory MCL — dedicated Phase I/randomized Phase II design
NCT02603445	Phase 1	Completed	20	BCL201 + idelalisib in follicular lymphoma and MCL; safety/tolerability primary endpoint
NCT01796470	Phase 2	Terminated	66	Entospletinib + idelalisib in relapsed/refractory hematologic malignancies incl. MCL
NCT02457598	Phase 1	Terminated	203	Tirabrutinib combined with targeted anti-cancer therapies (incl. idelalisib) in B-cell malignancies incl. MCL
NCT03151057	Phase 1	Terminated	16	Idelalisib as post-allogeneic HSCT maintenance in B-cell malignancies
NCT02824159	N/A	Completed	121	Real-world PK/toxicity correlation of ibrutinib and idelalisib in hematological malignancies including MCL
NCT04985214	N/A	Unknown	464	Quality of life in lymphoma patients on oral therapies, including idelalisib for MCL
NCT03740529	Phase 1/2	Completed	803	Pirtobrutinib in CLL/SLL and NHL — idelalisib appears only as background/prior therapy, not the study drug

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24795031	2014	Cohort	Cancer Discovery	Idelalisib showed measurable single-agent activity in heavily pretreated relapsed/refractory MCL patients
24615778	2014	Phase 1 clinical study	Blood	48-week Phase 1 study of idelalisib (50–350 mg) in 40 patients with relapsed/refractory MCL; reported ORR, PFS, DOR
27342398	2017	Preclinical	Clin Cancer Res	Idelalisib disrupts translation-regulatory mechanisms to suppress MCL cell growth
33850273	2022	Preclinical	Acta Pharmacol Sin	P300/CBP inhibitor A-485 overcomes intrinsic idelalisib resistance in MCL cells in vitro/in vivo
40466505	2025	Preclinical	Phytomedicine	CBX5 loss drives PI3Kδ inhibitor resistance in MCL; propolis restores idelalisib sensitivity via ferroptosis
38815797	2024	Preclinical	Cancer Letters	Idelalisib enhances anti-tumor effect of CDK4/6 inhibitor palbociclib via PLK1 in relapsed/refractory MCL and DLBCL
28295729	2017	Review	J Intern Med	Reviews BCR-pathway-targeted agents; notes idelalisib's established role across CLL and MCL
24974852	2014	Review	Br J Haematol	Overview of current and novel agents (incl. PI3K-pathway inhibitors) for MCL
26360791	2015	Review	Expert Opin Pharmacother	Review of treatment options for MCL, including targeted BCR-pathway agents
23512567	2013	Review	Curr Treat Options Oncol	Current and emerging therapies in MCL

Germany Market Information

No marketing authorizations are listed in the evidence pack (total_licenses: 0, market_status: 未上市). This most likely reflects an incomplete data pull rather than genuine absence from the market, since idelalisib (brand name Zydelig®) is externally documented as EMA-approved for CLL and relapsed follicular lymphoma — a discrepancy this evidence pack itself flags in the rationale for the "B-cell neoplasm" prediction. This regulatory-status field should be independently verified (see DG001) before any go/no-go decision is finalized.

Cytotoxicity

Idelalisib is an antineoplastic agent (approved oncology indication; kinase-inhibitor class), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (PI3Kδ-selective small-molecule kinase inhibitor; non-cytotoxic mechanism)
Myelosuppression Risk	Not quantifiable from this evidence pack (safety data flagged as data gap). Literature in this pack references neutropenia and cytopenia monitoring in idelalisib-treated patients — please refer to the package insert
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. All structured safety fields in this evidence pack (key_warnings, contraindications, ddi) are marked as data gaps, and this is flagged as a Blocking gap (DG001) that prevents entry into the S1 safety pre-assessment stage.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence specific to idelalisib in MCL is currently limited to completed Phase 1 trials and preclinical mechanistic studies (Evidence Level L3, decision stage S2, TxGNN's own recommendation is "Research Question"), with no completed Phase 2/3 confirmatory trial for this indication. Combined with a blocking data gap in TFDA/label safety information (DG001), a full safety and efficacy assessment cannot yet be completed.

To proceed, the following is needed:

Retrieve and parse the official product label (TFDA/EMA) to resolve DG001 and enable S1 safety review
Confirm mechanism-of-action documentation via DrugBank to resolve DG002
Independently verify true German/Taiwan marketing and licensing status (current "not marketed / 0 licenses" appears inconsistent with idelalisib's known global approval history)
Monitor for initiation of a dedicated Phase 2/3 trial in relapsed/refractory MCL
Establish a safety monitoring plan addressing known class-effect toxicities of PI3Kδ inhibitors (hepatotoxicity, colitis/diarrhea, pneumonitis, opportunistic infection) once label data is available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.